Literature DB >> 977942

Effects of C-reactive protein on platelet function. II. Inhibition by CRP of platelet reactivities stimulated by poly-L-lysine, ADP, epinephrine, and collagen.

B A Fiedel, H Gewurz.   

Abstract

It was recently demonstrated that C-reactive protein (CRP)4 inhibits the response of human platelets to heataggregated human gamma-globulin and thrombin and that this inhibition is characterized by a dose-dependent reduction in aggregation, activation of platelet factor 3 (PF3), and release of beta-glucuronidase. In the present experiments, CRP was found also to inhibit the ability of washed human platelets to aggregate in response to poly-L-lysine (PLL); in these experiments, the magnitude of the inhibitory effect was dependent upon the m.w. of PLL used as the stimulating agent, and was more effective with low (15,000 daltons) than with high (400,000 daltons) m.w. polymers. CRP similarly inhibited ADP- and epinephrine-stimulated platelet aggregation in platelet-rich plasma (PRP), and this was characterized by relatively minimal suppression of the primary wave of aggregation. CRP also inhibited the platelet aggregation induced by collagen in PRP, although it had no effect upon the adherence of platelets to collagen. Finally, CRP inhibited the activation of PF3 and the release of serotonin during stimulation of platelets with ADP, and this inhibition was temporally related to the onset of the secondary wave of aggregation. These experiments extend the platelet reactivities inhibited by CRP, show that CRP expresses its inhibitory capacity in platelet-rich plasma as well as upon isolated platelets, raise the possibility that CRP exercises its effects by inhibiting or interfering with the release and/or utilization of endogenous platelet ADP, and support the concept that CRP plays an important role in the control of platelet responsiveness to a variety of stimuli during acute inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 977942

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Comparison of the enzymatic sensitivities of the platelet receptor for human C-reactive protein and its functional relationship to the platelet IgG Fc receptor.

Authors:  B A Fiedel; J N Siegel; H Gewurz; R M Simpson; J M Izzi
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

2.  Activation of platelets by modified C-reactive protein.

Authors:  B A Fiedel; R M Simpson; H Gewurz
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

3.  Platelet inhibitory effects of CRP preparations are due to a co-isolating low molecular weight factor.

Authors:  B A Fiedel; L A Potempa; M E Frenzke; R M Simpson; H Gewurz
Journal:  Immunology       Date:  1982-01       Impact factor: 7.397

4.  Activation of human platelets by platelet activating factor (PAF) derived from sensitized rabbit basophils.

Authors:  M C O'Donnell; P M Henson; B A Fiedel
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

Review 5.  The Multiple Faces of C-Reactive Protein-Physiological and Pathophysiological Implications in Cardiovascular Disease.

Authors:  Magdalena Boncler; Yi Wu; Cezary Watala
Journal:  Molecules       Date:  2019-05-30       Impact factor: 4.927

6.  Staphylococcus aureus increases platelet reactivity in patients with infective endocarditis.

Authors:  Amin Polzin; Lisa Dannenberg; René M'Pembele; Philipp Mourikis; David Naguib; Saif Zako; Carolin Helten; Tobias Petzold; Bodo Levkau; Thomas Hohlfeld; Mareike Barth; Tobias Zeus; Stephan Sixt; Ragnar Huhn; Payam Akhyari; Artur Lichtenberg; Malte Kelm; Till Hoffmann
Journal:  Sci Rep       Date:  2022-07-28       Impact factor: 4.996

7.  Hamster female protein. A new Pentraxin structurally and functionally similar to C-reactive protein and amyloid P component.

Authors:  J E Coe; S S Margossian; H S Slayter; J A Sogn
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

Review 8.  Reduction of C-reactive protein and the use of anti-hypertensives.

Authors:  Carmine Savoia; Ernesto L Schiffrin
Journal:  Vasc Health Risk Manag       Date:  2007
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.